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muscarinic receptor or beta-adrenergic receptor, or both?Overactive bladder (OAB) symptoms presents in both sexes in
a great variety of forms: idiopathic, after bladder infection, and
in association with neurologic disorders. One presentation of
overactive bladder is persistent storage symptoms after transure-
thral resection of the prostate (TURP), which happens in approx-
imately 30% of patients. The cause for persistent storage
symptoms after TURP is multifactorial. Storage symptoms caused
by pre-existing neurological disorders such as stroke are ex-
pected to persist after TURP. Irreversible bladder outlet
obstruction-induced bladder denervation is another possibility.
Aging is also a risk factor.1 Treatment for post-TURP storage
symptom should theoretically be similar to the ordinary form
of OAB. This is why studies on pharmacotherapy for persistent
OAB after TURP are scarce.
In this issue of Urological Science, Chughtai et al2 present their
results of a pilot study that used fesoterodine to treat persistent
OAB symptoms. During 7 months of follow up, they found trends
of improvement in the mean number of nocturia episodes, the In-
ternational Prostate Symptom Score (IPSS) storage subscore, and
quality of life score.
A limitation of this pilot study is the small number of patients.
However, it is very likely that the improvement would be statisti-
cally signiﬁcant if the case number were sufﬁciently adequate.
The withdrawal rate in Chughtai et al's study was notably
highdapproximately one-third of patientsdduring a 7-month
follow-up period. Intolerable side effects such as constipation,
dry mouth and dry eye, which are typical adverse effects of anti-
muscarinics, were the major reasons patients discontinued feso-
terodine. The rate of persistence with antimuscarinics for OAB is
low, approximately only 30% at 12 months.3 The leading cause
for the low compliance rate of antimuscarinics is their adverse
effects. There have been multiple attempts to reduce the adverse
effects of antimuscarinics such as searching for compounds that
are more bladder selective, changing the route of administration,
and changing to an extended-release formulation. However, even
with these efforts, the adverse effects of antimuscarinics are suf-
ﬁcient enough to cause a low drug persistence rate.
The emergence of b3 adrenergic agonist is timely with regard to
improving drug adherence. In this issue of Urological Science, Kuo
et al4 report a randomized double-blind, placebo- and active-
controlled trial that compared treatment efﬁcacy between mirabe-
gron, tolterodine, and placebo on OAB symptoms in Taiwanese pa-
tients. They demonstrated that mirabegron at a dose of 50 mg once
daily for 12 weeks was superior to a placebo in reducing urinary
frequency. The study also showed that mirabegron had a goodhttp://dx.doi.org/10.1016/j.urols.2015.01.001
1879-5226/Copyright © 2015, Taiwan Urological Association. Published by Elsevier Taiwsafety proﬁle with a low incidence of adverse events, which was
similar to that in the placebo group. The incidence of dry mouth
was as low as 5.9%, which was lower than its incidence with anti-
muscarinics. The incidence of cardiovascular side effects was also
low, particularly for b-adrenergic agonists.
Good treatment efﬁcacy on OAB symptoms and satisfactory
safety proﬁle of mirabegron demonstrated in this Taiwanese study
are similar to those of studies conducted in Japan, the United States
of America, and Europe. Because of its low incidence of adverse ef-
fects, mirabegron is expected to have a higher drug persistence rate.
In this Taiwanese mirabegron study, >75% of patients had previ-
ously used drug medications for OAB, primarily antimuscarinics
agents, which indicates that OAB that is refractory to antimuscar-
inics can bewell managed with a b3 adrenergic agonist. This ﬁnding
is in accordance with a report by a post hoc subgroup analysis of a
clinical trial, which showed that mirabegron beneﬁts OAB patients
who were antimuscarinic treatment-naive and who had received
prior antimuscarinic treatment.5 Mirabegron may provide new
hope for patients with refractory OAB who have a poor response
to antimuscarinics.
Could the combination of antimuscarinics and b3 agonists be
used to treat OAB that is not responding well to either agent or
could the combination be used to reduce adverse effects of either
agent? A published Phase 2 study has provided a preliminary
answer. Abrams et al6 report that combination therapy with solife-
nacin and mirabegron signiﬁcantly improved OAB symptoms,
compared to solifenacin (5 mg) monotherapy. They concluded
that combination therapy improves OAB symptoms and has similar
safety and acceptability.6 Further study may elucidate the most
appropriate dose combination of antimuscarinic and b3 agonist.
In conclusion, the introduction of a b3 agonist has signiﬁcantly
advanced the care for OAB patients. The deﬁnition of refractory
OAB should be revised from “refractory” to “only antimuscarinics”,
“resistant to monotherapy with antimuscarinics or b3 agonists”, or
“combination therapy with both classes of drugs”.
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